Therapeutic Advances in Chronic Disease (Jan 2021)

The five-repetition sit-to-stand test is a predictive factor of severe exacerbations in COPD

  • Francesc Medina-Mirapeix,
  • Roberto Bernabeu-Mora,
  • Elisa Valera-Novella,
  • Mariano Gacto-Sánchez,
  • Myriam Bernabeu-Mora,
  • María Piedad Sánchez-Martínez

DOI
https://doi.org/10.1177/2040622320986718
Journal volume & issue
Vol. 12

Abstract

Read online

Background: Although the six-minute-walk test (6MWT) has been used to predict chronic obstructive pulmonary disease (COPD) exacerbations, additional research is necessary to identify more rapid, simpler tests that are directly associated with exacerbations, such as the five-repetition sit-to-stand (5STS) test and 4-m gait speed (4MGS) test. Aims: To determine the ability of the 5STS and 4MGS tests in predicting severe exacerbations in stable COPD over the following year, and to assess the ability of the best prognostic test to identify patients at high risk of hospital admission correctly. Methods: This prospective study included 137 patients with stable COPD. Multiple logistic regression models were constructed to assess whether the 6MWT, 5STS, and 4MGS tests were associated with severe exacerbations in the year following the test. Receiver-operating characteristic curves and the area under the curve (AUC) were evaluated to determine the accuracy of each test for identifying patients with severe exacerbations. Results: Scores of <350 m for the 6WMT and ⩽2 for the 5STS test were associated with severe exacerbations in the model adjusted for age and the number of exacerbations in the previous year. The 5STS test and the 6MWT had very similar predictive and discriminative abilities. Odds ratios were 3.20 (95% confidence interval [CI] 1.14–8.96) and 3.84 (95% CI 1.14–12.94) and AUCs were 0.793 (95% CI 0.704–0.882) and 0.783 (95% CI 0.686–0.879), respectively. Conclusions: The 5STS test predicted the risk of severe exacerbation within the following year among patients with COPD. The 5STS test could replace the 6MWT for identifying patients at high risk of hospital admission.